阿托伐他汀对急性冠状动脉综合征患者血清髓过氧化酶和高敏C反应蛋白的影响
DOI:
作者:
作者单位:

作者简介:

通讯作者:

基金项目:


The Effects of Atorvastatin on Serum Myeloperoxidase and High Sensitive C-Reactive Protein Concentrations in Patients with Acute Coronary Syndrome
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
    摘要:

    目的探讨阿托伐他汀对急性冠状动脉综合征患者血清髓过氧化酶及高敏C反应蛋白的影响及其可能机制。方法将急性冠状动脉综合征患者随机分为阿托伐他汀组和对照组,分别检测治疗前后血清髓过氧化酶和高敏C反应蛋白的浓度。结果阿托伐他汀组和对照组血清髓过氧化酶和高敏C反应蛋白浓度均明显下降(p<0.05);但阿托伐他汀组较对照组下降更加明显(p<0.05)。髓过氧化酶和高敏C反应蛋白的下降没有相关性(r=0.124,P=0.068)。结论阿托伐他汀能降低急性冠状动脉综合征患者血清髓过氧化酶和高敏C反应蛋白水平,其可能部分解释他汀类药物的抗炎作用。

    Abstract:

    Aim To investigate the effects of atorvastatin on serum myeloperoxidase(MPO) and high sensitive C-reactive protein(hs-CRP) concentrations in patients with acute coronary syndrome(ACS). Methods Seventy-eight patients with ACS were randomly separated in atorvastatin treatment group and control group.The serum concentrations of MPO and hs-CRP were measured before and after treatment. Results Serum MPO and hs-CRP concentrations were significantly lower after treatment in the two groups(p<0.05).Compared with control group,serum MPO and hs-CRP concentrations were reduced significantly in atorvastatin group(p<0.05).There were no correlations between the reduction of MPO and hs-CRP(r=0.124,P=0.068). Conclusions Atorvastatin reduced serum MPO and hs-CRP concentrations in patients with ACS.These effects may explain some clinical benefits of statins in the treatment of these patients.

    参考文献
    相似文献
    引证文献
引用本文

周滔,周胜华,祁述善,沈向前,周宏年.阿托伐他汀对急性冠状动脉综合征患者血清髓过氧化酶和高敏C反应蛋白的影响[J].中国动脉硬化杂志,2006,14(8):721~722.

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
历史
  • 收稿日期:2006-01-04
  • 最后修改日期:2006-07-14
  • 录用日期:
  • 在线发布日期: